ActiveGRANT
DoW Multiple Sclerosis Clinical Trial Award
Department of DefenseDept. of the Army -- USAMRAA
AI Overview
This DoD program funds clinical trials for multiple sclerosis treatments, from early-stage proof-of-concept to phase 2 studies. It supports testing of new drugs, biologics, devices, and emerging technologies to improve MS management.
This summary is AI-generated from the official solicitation.
Key Details
Agency
Department of Defense
Funding Amount
—
Release Date
May 5, 2026
Due Date
August 13, 2026
Official Description
<p><strong>Summary:</strong> The fiscal year 2026 (FY26) Multiple Sclerosis Research Program (MSRP) Clinical Trial Award (CTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of multiple sclerosis. All applications must address at least one of the FY26 MSRP CTA focus areas. Clinical trials may evaluate promising new products, pharmacologic agents (drugs or biologics), devices, clinical guidance and/or emerging ap...
View on official sourceChange History
Opportunity AddedMay 5, 2026 at 3:47 PM
DoW Multiple Sclerosis Clinical Trial Award
New Grants.gov opportunity: DoW Multiple Sclerosis Clinical Trial Award
Similar Opportunities
Get Alerts for Opportunities Like This
RallyProp monitors thousands of funding sources and sends instant alerts when opportunities match your technology and capabilities.
Start Free Trial